WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring ...
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination product ...
Credit: Getty Images. VP-102 is a drug-device combination product that delivers cantharidin (0.7% w/v) via a single-use applicator. The Food and Drug Administration (FDA) has accepted for review the ...
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application for cantharidin 0.7% topical solution (VP-102; Verrica Pharmaceuticals) for the treatment of molluscum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results